The CDK4 / 6 inhibitors market is estimated to grow from USD 11.34 billion in 2024 to reach USD 13.51 billion in 2025 and USD 55.92 billion by 2035, representing a higher CAGR of 15.3% during the forecast period. According to the Breast Cancer Facts and Statistics, in 2025, nearly 3,16,950 women will be diagnosed with invasive breast cancer. According to CDK4 / 6 inhibitors market analysis, currently North America is dominating the market by holding 45% of the overall revenue share.

The global Fc and glycoengineered antibodies market, valued at USD 42.3 billion in 2025, is projected to reach USD 45.7 billion in 2026 and USD 38.7 billion by 2035, during the forecast period 2026 to 2035. Antibody based pharmacological interventions have become one of the fastest growing segments of the biopharmaceutical industry, with over 120 approved monoclonal antibodies, and close to 900 registered trials for clinical evaluation. In fact, it is worth highlighting that, these interven...

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035. It is worth mentioning that a significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. Driven by the growing usage of...

The antibiotics market size, valued at USD 37 billion in 2025, is projected to reach USD 37 billion in 2026 and USD 41 billion by 2035, representing a CAGR of 1.2% during the forecast period 2026 to 2035. In terms of type of drug class, the other drug class segment secures >60% of the overall revenue share of the global market. Antibiotics has two types of therapies, such as monotherapies and combination therapies. Of which, monotherapy holds the majority of the share (~80%). With regards to t...

The global gene switch market, valued at USD 795 million in 2025, is projected to reach USD 899 million in 2026 and USD 2,478 billion by 2035, with a 11.93% CAGR during the forecast period 2026 to 2035. Notably, in the past few years, close to 30 cell and gene therapy products have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. However, despite various advantages, adverse events are associated with...

he broader focus will be on the development of tailored therapeutic drugs, including gene therapies, companion animal vaccines and recombinant proteins that can address animal’s unique needs.For instance, in February 2025, Bharat Biotech (India) announced that its Biolumpivaxin (vaccine for lumpy skin disease) has received the Central Drug Standards Control Organization license for cattle’s and buffaloes. As more market players continue to develop advanced biologics, it is expected that vete...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The global complementary and alternative medicine market, valued at USD 160.65 billion in 2024, is projected to reach USD 209.67 billion in 2025 and USD 1,605.23 billion by 2035, representing a CAGR of 22.6% during the forecast period. Currently, traditional alternative medicine accounts for the highest complementary and alternative medicine share (over 35%). Among these, herbal supplements hold the highest complementary and alternative medicine market size (with a share of 40%). Pain managemen...

The global antimalarial drugs market size, valued at USD 1.13 billion in 2024, is projected to reach USD 1.19 billion in 2025 and USD 1.75 billion by 2035, representing a CAGR of 3.9% during the forecast period. The antimalarial drug industry is constantly witnessing an upward trajectory as players are focusing on the development of resistance-free antimalarial drugs to mitigate the concern of drug resistance. A recent success in antimalarial drugs has been shared by the Karine Le Roche, (profes...

The probiotics market, valued at USD 70.9 billion in 2024, is project to reach USD 76.2 billion in 2025 and USD 165.1 billion by 2035, representing a CAGR of 8.0% during the forecast period 2025 to 2035. In terms of type of product, the food and beverages segment holds the highest share (nearly 80%) of the market.  The nutritional supplements segment is capturing the majority of the market share (~60%) in the year 2025, with respect to type of probiotic dietary supplement segment. In terms o...

Major players like AstraZeneca (UK), Pfizer (US), Merck (US), and Roche (Switzerland) are making significant investments to achieve sustainability goals and reduce their environmental impact. They are adopting strategies such as green chemistry, renewable energy integration, and upgrading manufacturing facilities.Roche (Switzerland) has committed a massive investment of USD 50 billion over five years into its US pharmaceutical and diagnostics operations. This investment includes expanding and up...

With accelerated approval from the USFDA, several industrial players are taking strategic initiatives for technological innovations that help to explore more applications autologous cell therapies beyond cancer and autoimmune diseases. For instance, in November 2024, Nature Cell (a Korean biotechnology company) announced the success of autologous adipose stem cells that are delivered into spinal cavity of patient to treat Parkinson’s disease. This therapy has been developed by Japan Angel Stem...

The global allogeneic cell therapy market valued at USD 50.0 million in 2025, is projected to grow to USD 52.4 million in 2026 and USD 1,629.6 million by 2035, representing a CAGR of 46.5% during the forecast period 2026 to 2035. Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, such as hematological malignancies and neurological disorders have received approval from various regulatory authorities, globally. In December 2022, the European Commission...

The global super generics market, valued at USD 90.9 billion in 2025, is projected to reach USD 98.8 billion in 2026 and USD 199.5 billion by 2035, with a 8.12% CAGR during the forecast period 2026 to 2035. In the pharmaceutical industry, super generic drugs represent improved versions of an original pharmaceutical drug that have lost their patent exclusivity. These modified pharmacological interventions are commonly referred to as complex generics / value added generics. These enhanced versi...

The global pharmacy market, valued at USD 2.5 trillion in 2025, is projected to reach USD 2.6 trillion in 2026 and USD 4.1 trillion by 2035, with a 5% CAGR during the forecast period 2026 to 2035. According to the US health department, around 133 million Americans live with at least one chronic disease. In order to address this, the pharmacy industry, comprising both independent stores and chains are offering a wide range of prescription drugs, over-the-counter drugs, medical devices and other...

The global monoclonal antibody market size, valued at USD 249.95 billion in 2024, is projected to reach USD 283.86 billion in 2025 and USD 816.33 billion by 2035, representing a CAGR of 11.1% during the forecast period. In terms of applications area, the oncology segment captures the highest market share (nearly 50%) of monoclonal antibody market. As per the regional analysis, North America holds 47% monoclonal antibodies mabs market share. Currently, in vitro production method segment holds the...

It is worth noting that the growing foundational research on diseases, genomics, gene therapies and targeted drugs has necessitated the demand for oligonucleotide synthesizers in the upcoming years. In addition, the need for advanced diagnostic technologies due to the rising risk of chronic diseases is fueling the demand for oligonucleotide synthesizers.Considering the ongoing demand, several industrial players are encouraging strategic initiatives to develop next generation oligonucleotide synt...

Market players, such as Mckesson (US), ARxIUM (Canada), Capsa Healthcare (US) and KUKA (Germany), are increasingly leveraging strategi initiatives for innovations. For instance, in July 2025, Capsa Healthcare (US) launched its consolidated services pharmacy platform (CSPP), industry’s first integrated scalable system that unifies the central fill automation and enterprise-wide distribution management into single system. Owing to the ongoing demand and rising industrial player initiatives, we b...

The global cell and gene therapy manufacturing market size, valued at USD 11.9 billion in 2024, is projected to reach USD 15.1 billion in 2025 and USD 160.0 billion by 2035, representing a CAGR of 26.64% during the forecast period. According to our projection, North America has the highest share (45%) of the market and the trend of dominance is likely to remain unchanged during the forecast period. North American region is currently dominating the industry with the highest share of 45%. . Accord...

Owing to its significances and rising demand for targeted drug delivery devices, several industrial players are undertaking initiatives to develop nanomedicine for drug delivery. For instance, in February 2025, IIT Madras (Indian Institute of Technology, Madras, India) researcher’s team have developed a patented nanotechnology for breast cancer treatment. Owing to the successful outcomes, this researcher team is seeking partnerships with pharmaceutical industries for clinical trials and commer...